CD24Fc: an emerging COVID-19 therapy

Lancet Infect Dis. 2022 May;22(5):565-567. doi: 10.1016/S1473-3099(22)00125-6. Epub 2022 Mar 11.

Authors

Christina M Eckhardt¹, Max R O'Donnell²

Affiliations

¹ Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: cme2113@cumc.columbia.edu.
² Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Epidemiology, Columbia University Irving Medical Center, New York, NY 10032, USA.

No abstract available

Publication types

Comment

MeSH terms

COVID-19*
Humans
Immunologic Factors
SARS-CoV-2

Substances

Immunologic Factors